Agios Pharm Total Liabilities
Agios Pharm total liabilities. Based on the latest financial reports, Agios Pharm (AGIO) has total liabilities worth $82.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See AGIO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Agios Pharm (2011–2025)
Total liabilities of Agios Pharm from 2011 to 2025. This chart illustrates how Agios Pharm's total liabilities have evolved over time, based on quarterly financial data. Check AGIO asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Agios Pharm Competitors by Total Liabilities
The table below lists competitors of Agios Pharm ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Astronics Corporation
NASDAQ:ATRO
|
USA | $566.60 Million |
|
MVV Energie AG
F:MVV1
|
Germany | €4.11 Billion |
|
Guangdong Topstar Technology Co Ltd
SHE:300607
|
China | CN¥3.10 Billion |
|
Tianma Microelectronics Co Ltd
SHE:000050
|
China | CN¥45.02 Billion |
|
Test Research Inc
TW:3030
|
Taiwan | NT$2.95 Billion |
|
Karooooo Ltd
NASDAQ:KARO
|
USA | $2.66 Billion |
|
Surgery Partners Inc
NASDAQ:SGRY
|
USA | $4.39 Billion |
|
Aehr Test Systems
NASDAQ:AEHR
|
USA | $27.18 Million |
Liability Composition Analysis (2011–2025)
This chart breaks down Agios Pharm's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Agios Pharm.
Liquidity & Leverage Metrics
Agios Pharm Total Liabilities Ratios Explained
Agios Pharm total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Agios Pharm's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Agios Pharm (2011–2025)
The table below shows the annual total liabilities of Agios Pharm from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $104.11 Million | -14.83% |
| 2024-12-31 | $122.24 Million | -3.06% |
| 2023-12-31 | $126.10 Million | -8.56% |
| 2022-12-31 | $137.90 Million | -5.39% |
| 2021-12-31 | $145.76 Million | -67.86% |
| 2020-12-31 | $453.45 Million | +81.23% |
| 2019-12-31 | $250.21 Million | +46.39% |
| 2018-12-31 | $170.92 Million | -28.45% |
| 2017-12-31 | $238.89 Million | -8.30% |
| 2016-12-31 | $260.50 Million | +247.58% |
| 2015-12-31 | $74.95 Million | +10.97% |
| 2014-12-31 | $67.54 Million | -3.13% |
| 2013-12-31 | $69.72 Million | -25.12% |
| 2012-12-31 | $93.11 Million | -29.10% |
| 2011-12-31 | $131.33 Million | -- |
About Agios Pharm
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more